TARS insider transaction filings
Tarsus Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen TARS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 15 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 14 legs across 6 filings by 4 insiders — 62,595 shares, $5,192,759 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 11,675 shares @ $78.33 ($914,503) by LINK WILLIAM J PHD, filed 2026-09-17.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lin Elizabeth Yeu — Chief Medical Officer | 2 | — | 7 legs · 25,531 sh · $2,118,875 | — |
| Azamian Bobak R. — President/CEO and Board Chair, Director | 2 | — | 3 legs · 20,000 sh · $1,706,200 | — |
| LINK WILLIAM J PHD — Director | 2 | — | 3 legs · 12,500 sh · $979,744 | 5 |
| Neervannan Seshadri — Chief Operating Officer | 1 | — | 1 leg · 4,564 sh · $387,940 | — |
| PYOTT DAVID E I — Director | 2 | — | — | 5 |
| YARNO WENDY L — Director | 2 | — | — | 5 |
| CHAUDHURI BHASKAR — Director | 1 | — | — | 2 |
| Goldberg Andrew D. — Director | 1 | — | — | 2 |
| Goodrich Katherine — Director | 1 | — | — | 2 |
| Morrison Scott W — Director | 1 | — | — | 2 |
Recent Form 4 filings — Tarsus Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | PYOTT DAVID E I — Director | Option exercise (M): 201 · Option exercise (M): 201 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | LINK WILLIAM J PHD — Director | Option exercise (M): 201 · Sale (S): 11,675 @ $78.33 · Sale (S): 759 @ $79 · Sale (S): 66 @ $80.01 · Option exercise (M): 201 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | YARNO WENDY L — Director | Option exercise (M): 302 · Option exercise (M): 302 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Sale (S): 7,100 @ $90.27 · Sale (S): 2,900 @ $91.27 | EDGAR |
| 2026-09-09 | 4 | Neervannan Seshadri — Chief Operating Officer | Sale (S): 4,564 @ $85 | EDGAR |
| 2026-09-09 | 4 | Lin Elizabeth Yeu — Chief Medical Officer | Sale (S): 5,387 @ $85 · Sale (S): 5,386 @ $90 · Sale (S): 1,590 @ $85 · Sale (S): 1,590 @ $90 | EDGAR |
| 2026-09-03 | 4 | Lin Elizabeth Yeu — Chief Medical Officer | Sale (S): 4,601 @ $73.86 · Sale (S): 5,387 @ $80 · Sale (S): 1,590 @ $80 | EDGAR |
| 2026-09-03 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Sale (S): 10,000 @ $80.06 | EDGAR |
| 2026-06-29 | 4 | Goodrich Katherine — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Goldberg Andrew D. — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Morrison Scott W — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | CHAUDHURI BHASKAR — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | LINK WILLIAM J PHD — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | YARNO WENDY L — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 1,209 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | PYOTT DAVID E I — Director | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Sale (S): 4,582 @ $61.24 · Sale (S): 5,418 @ $61.81 | EDGAR |
| 2026-06-17 | 4 | Goodrich Katherine — Director | Sale (S): 2,954 @ $62.08 | EDGAR |
| 2026-06-17 | 4 | Farrow Jeffrey S — See Remarks | Option exercise (M): 27,881 · Sale (S): 14,396 @ $60.95 · Option exercise (M): 27,881 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | LINK WILLIAM J PHD — Director | Sale (S): 10,572 @ $61.97 · Sale (S): 1,928 @ $62.94 | EDGAR |
| 2026-06-16 | 4 | Goodrich Katherine — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Goldberg Andrew D. — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Morrison Scott W — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | CHAUDHURI BHASKAR — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | LINK WILLIAM J PHD — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | YARNO WENDY L — Director | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | PYOTT DAVID E I — Director | Option exercise (M): 1,383 · Option exercise (M): 1,383 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Neervannan Seshadri — Chief Operating Officer | Sale (S): 2,989 @ $66.75 | EDGAR |
| 2026-03-19 | 4 | Lin Elizabeth Yeu — Chief Medical Officer | Sale (S): 375 @ $69.42 · Sale (S): 379 @ $68.71 · Sale (S): 390 @ $67 | EDGAR |
| 2026-03-19 | 4 | Wahl Bryan — General Counsel | Sale (S): 4,084 @ $69.42 · Sale (S): 4,125 @ $68.71 · Sale (S): 4,231 @ $67 | EDGAR |
| 2026-03-19 | 4 | Whitfield Dianne C. — Chief Human Resources Officer | Sale (S): 4,029 @ $69.42 · Sale (S): 4,071 @ $68.71 · Sale (S): 4,174 @ $67 | EDGAR |
| 2026-03-19 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Sale (S): 10,972 @ $69.42 · Sale (S): 11,667 @ $68.71 · Sale (S): 11,964 @ $67 | EDGAR |
| 2026-03-19 | 4 | Neervannan Seshadri — Chief Operating Officer | Sale (S): 3,125 @ $69.42 · Sale (S): 3,610 @ $68.71 · Sale (S): 4,589 @ $67 | EDGAR |
| 2026-03-19 | 4 | Mottiwala Aziz — Chief Commercial Officer | Sale (S): 4,286 @ $69.42 · Sale (S): 4,330 @ $68.71 · Sale (S): 4,440 @ $67 | EDGAR |
| 2026-03-19 | 4 | Farrow Jeffrey S — See Remarks | Sale (S): 2,111 @ $69.42 · Sale (S): 2,133 @ $68.71 · Sale (S): 2,186 @ $67 | EDGAR |
| 2026-03-18 | 4 | LINK WILLIAM J PHD — Director | Sale (S): 3,629 @ $68.09 · Sale (S): 8,378 @ $69.03 · Sale (S): 493 @ $69.75 | EDGAR |
| 2026-03-17 | 4 | Lin Elizabeth Yeu — Chief Medical Officer | Option exercise (M): 2,511 · Option exercise (M): 2,511 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Wahl Bryan — General Counsel | Option exercise (M): 24,236 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 7,248 (derivative) @ $0 · Option exercise (M): 7,176 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Whitfield Dianne C. — Chief Human Resources Officer | Option exercise (M): 23,909 · Option exercise (M): 4,463 (derivative) @ $0 · Option exercise (M): 7,248 (derivative) @ $0 · Option exercise (M): 7,176 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Option exercise (M): 66,274 · Option exercise (M): 11,300 (derivative) @ $0 · Option exercise (M): 16,975 (derivative) @ $0 · Option exercise (M): 23,121 (derivative) @ $0 · Option exercise (M): 14,878 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Neervannan Seshadri — Chief Operating Officer | Option exercise (M): 26,287 · Option exercise (M): 5,097 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Mottiwala Aziz — Chief Commercial Officer | Option exercise (M): 26,482 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,524 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Farrow Jeffrey S — See Remarks | Option exercise (M): 13,042 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lin Elizabeth Yeu — Chief Medical Officer | Grant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Wahl Bryan — General Counsel | Grant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Whitfield Dianne C. — Chief Human Resources Officer | Grant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Azamian Bobak R. — President/CEO and Board Chair, Director | Grant/award (A): 96,723 (derivative) @ $0 · Grant/award (A): 60,776 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Neervannan Seshadri — Chief Operating Officer | Grant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Mottiwala Aziz — Chief Commercial Officer | Grant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Farrow Jeffrey S — See Remarks | Grant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Neervannan Seshadri — Chief Operating Officer | Sale (S): 8,366 @ $76.67 | EDGAR |
Recent 8-K events — Tarsus Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TARS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →